The experimental antipsychotic evenamide is associated with reduced severity of symptoms when added to an existing antipsychotic in treatment-resistant schizophrenia (TRS), new research suggests.The topline results from an exploratory study, which were released by the developer Newron Pharmaceuticals, are "very encouraging," Stephen R. Marder, MD, professor of psychiatry and biobehavioral sciences at the University of California Los Angeles (UCLA), said in a company news release.
[
add
]
[
|
|
...
]